Physician profile
Shannon Sheets
NPI 1295308716
$812.72
in general payments reported to CMS, 2019-2025
20 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $136 · 2023: $146 · 2024: $140 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.47 | 2022 | |
| Pfizer INC. | $59.83 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $48.81 | 2024-2025 | |
| Incyte Corporation | $47.68 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $41.65 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $37.49 | 2025 | Livtencity |
| Celgene Corporation | $34.69 | 2023 | Reblozyl |
| Lilly USA, LLC | $28.10 | 2023 | Jaypirca |
| Jazz Pharmaceuticals INC. | $28.02 | 2025 | |
| Astellas Pharma US INC | $27.74 | 2024-2025 | Cresemba |
| Daiichi Sankyo INC. | $25.08 | 2025 | Vanflyta |
| Legend Biotech USA INC. | $22.56 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.05 | 2023 | |
| Syndax Pharmaceuticals, INC. | $21.92 | 2025 | Revuforj |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $21.23 | 2025 | Enjaymo |
| Apellis Pharmaceuticals, INC. | $21.10 | 2025 | Empaveli |
| Adc Therapeutics America, INC. | $20.27 | 2022 | |
| Glaxosmithkline, LLC. | $18.61 | 2024 | Ojjaara |
| Merck Sharp & Dohme LLC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.